[Not Available].
出版信息
Can Urol Assoc J. 2009 Jun;3(3):200-204. doi: 10.5489/cuaj.1069.
Abstract
摘要
相似文献
1
[Not Available].
Can Urol Assoc J. 2009 Jun;3(3):200-204. doi: 10.5489/cuaj.1069.
引用本文的文献
1
Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021.
Can Urol Assoc J. 2021 Apr;15(4):84-97. doi: 10.5489/cuaj.7245.
2
Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.
Can Urol Assoc J. 2019 Oct;13(10):343-354. doi: 10.5489/cuaj.6256.
3
Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.
Can Urol Assoc J. 2017 Oct;11(10):310-320. doi: 10.5489/cuaj.4769.
4
Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update.
Can Urol Assoc J. 2015 May-Jun;9(5-6):164-70. doi: 10.5489/cuaj.2894.
5
Canadian guidelines for the management of small renal masses (SRM).
Can Urol Assoc J. 2015 May-Jun;9(5-6):160-3. doi: 10.5489/cuaj.2969.
6
Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013.
Can Urol Assoc J. 2013 Jul-Aug;7(7-8):238-43. doi: 10.5489/cuaj.536.
7
Management of kidney cancer: canadian kidney cancer forum consensus update 2011.
Can Urol Assoc J. 2012 Feb;6(1):16-22. doi: 10.5489/cuaj.11273.
8
Recent developments in kidney cancer.
Can Urol Assoc J. 2011 Jun;5(3):195-203. doi: 10.5489/cuaj.10148.
9
Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib.
Biologics. 2010 May 25;4:91-101. doi: 10.2147/btt.s6748.
10
Erratum.
Can Urol Assoc J. 2009 Aug;3(4):289.
本文引用的文献
1
Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma.
Can Urol Assoc J. 2009 Feb;3(1):73-6. doi: 10.5489/cuaj.1028.
2
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.
Cancer. 2009 Feb 15;115(4):776-83. doi: 10.1002/cncr.24051.
3
Robotic partial nephrectomy versus laparoscopic partial nephrectomy for renal cell carcinoma: single-surgeon analysis of >100 consecutive procedures.
Urology. 2009 Feb;73(2):306-10. doi: 10.1016/j.urology.2008.09.049. Epub 2008 Nov 26.
4
Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm.
J Urol. 2009 Jan;181(1):35-41. doi: 10.1016/j.juro.2008.09.025. Epub 2008 Nov 13.
5
Lymph node dissection in the management of renal cell carcinoma.
Urol Clin North Am. 2008 Nov;35(4):673-8; viii. doi: 10.1016/j.ucl.2008.07.011.
6
Robotic-assisted laparoscopic partial nephrectomy: surgical technique and clinical outcomes at 1 year.
BJU Int. 2009 Mar;103(5):663-8. doi: 10.1111/j.1464-410X.2008.08060.x. Epub 2008 Oct 6.
7
Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis.
Cancer. 2008 Nov 15;113(10):2671-80. doi: 10.1002/cncr.23896.
8
Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement.
Can Urol Assoc J. 2008 Jun;2(3):175-82.
9
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22.
10
Targeted drugs for metastatic renal cell carcinoma.
Lancet. 2007 Dec 22;370(9605):2071-3. doi: 10.1016/S0140-6736(07)61874-1.
Zotero 插件